DOCK3 and Parkinson disease: After 6 months of treatment, there were no statistically significant differences in change scores between the treatment groups on the MDS‐UPDRS part 1 (p = 0.98; Wilcoxon rank sum test), MDS‐UPDRS part 2 (p = 0.71; Wilcoxon rank sum test), MDS‐UPDRS part 3 (p = 0.54; Wilcoxon rank sum test), SAPS (p = 0.13; Welch's t‐test); MoCA (p = 0.28; χ2 test), PD‐CRS (p = 0.75; Welch's t‐test), HADS (p = 0.83; Welch's t‐test), ESS (p = 0.97 Welch's t‐test), and ALDS (p = 0.06; Welch's t‐test; Figure 4).